Conquering lung cancer: current status and prospects for the future
- PMID: 32199906
- DOI: 10.1016/j.pulmoe.2020.02.005
Conquering lung cancer: current status and prospects for the future
Abstract
Lung cancer is a major global health problem. Several strategies are required to conquer this cancer. Stricter implementations of tobacco control measures are necessary. Early detection programs should be implemented to decrease lung cancer mortality. Although chemotherapy remains a cornerstone of treatment, targeted therapies and immune checkpoint inhibitors improved treatment of metastatic cancers and are hoped to improve outcome of adjuvant and induction therapies. Novel immunotherapy approaches hold great promise. Better understanding of the molecular biology of lung cancer should lead to rational drug design.
Keywords: Chemotherapy; Immune checkpoint inhibitors; Multimodality therapy; Screening; Targeted therapies; Tobacco control.
Copyright © 2020. Published by Elsevier España, S.L.U.
Similar articles
-
Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.Jpn J Clin Oncol. 2021 Jan 1;51(1):28-36. doi: 10.1093/jjco/hyaa187. Jpn J Clin Oncol. 2021. PMID: 33147608 Review.
-
[A decade of checkpoint inhibitors: current standard of care and future trends].Dtsch Med Wochenschr. 2021 Sep;146(17):1108-1118. doi: 10.1055/a-1303-8820. Epub 2021 Aug 26. Dtsch Med Wochenschr. 2021. PMID: 34448187 Review. German.
-
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.Drug Resist Updat. 2017 May;32:1-15. doi: 10.1016/j.drup.2017.07.002. Epub 2017 Aug 19. Drug Resist Updat. 2017. PMID: 29145974 Review.
-
Multimodality Therapy for NSCLC.Cancer Treat Res. 2016;170:151-63. doi: 10.1007/978-3-319-40389-2_7. Cancer Treat Res. 2016. PMID: 27535393 Review.
-
Acute Myeloid Leukemia: Changing Treatment Paradigms and Novel Agents in Development.Curr Cancer Drug Targets. 2020;20(7):471-472. doi: 10.2174/156800962008200714125648. Curr Cancer Drug Targets. 2020. PMID: 32703130 No abstract available.
Cited by
-
The Roles of Imprinted SLC22A18 and SLC22A18AS Gene Overexpression Caused by Promoter CpG Island Hypomethylation as Diagnostic and Prognostic Biomarkers for Non-Small Cell Lung Cancer Patients.Cancers (Basel). 2020 Jul 27;12(8):2075. doi: 10.3390/cancers12082075. Cancers (Basel). 2020. PMID: 32726996 Free PMC article.
-
Impact of the COVID-19 Pandemic on the Diagnosis of Malignant Neoplasia of the Bronchus and Lung in the Burgos Region.Healthcare (Basel). 2024 Aug 22;12(16):1677. doi: 10.3390/healthcare12161677. Healthcare (Basel). 2024. PMID: 39201235 Free PMC article.
-
The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis.Appl Bionics Biomech. 2022 Jun 6;2022:2731744. doi: 10.1155/2022/2731744. eCollection 2022. Appl Bionics Biomech. 2022. Retraction in: Appl Bionics Biomech. 2023 Oct 4;2023:9873947. doi: 10.1155/2023/9873947. PMID: 35706510 Free PMC article. Retracted.
-
Harnessing EVs-ncRNA for Lung Cancer: From Oncogenic Pathways to Novel Diagnostic and Therapeutic Strategies.Int J Nanomedicine. 2025 Jul 14;20:9031-9054. doi: 10.2147/IJN.S528115. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40689018 Free PMC article. Review.
-
Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications.Mol Oncol. 2024 Feb;18(2):453-470. doi: 10.1002/1878-0261.13550. Epub 2023 Dec 21. Mol Oncol. 2024. PMID: 37943164 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical